Participated · Series A · Mar 2026

Ironlight Group is an Austin-based financial technology company developing infrastructure for global tokenized securities markets through its subsidiaries Ironlight Markets and Ironlight Technologies. Ironlight Markets operates a registered broker-dealer and an Alternative Trading System (ATS) under SEC Regulation ATS and FINRA oversight, while Ironlight Technologies provides platform and settlement options for tokenized securities. The company's ecosystem is designed to support tokenized private equity, structured products, fixed income, private credit, and real estate. Ironlight combines traditional market structure with blockchain-native atomic settlement to streamline post-trade workflows for institutions and wealth advisors. Following the Series A, the company plans to scale its ATS and platform capabilities to expand digital trading, distribution, and settlement systems. The company also appointed Greg Braca as Executive Chairman to help advance development of its marketplace.

Led · Series B · Apr 2021

Algorithm Sciences is a development-stage biopharmaceutical company focused on optimizing treatment for rare cardiovascular diseases (CVDs). The company’s lead product candidate targets rare CVDs and Algorithm Sciences says its tools and technologies can deliver therapies to achieve improved outcomes. Algorithm Sciences is a Laidlaw Venture Partners portfolio company. The company stated it will invest proceeds from the Series B to further develop its pipeline, including the lead product candidate for rare CVDs. The announcement was made in a press release dated April 20, 2021; no operating metrics such as revenue or user counts were disclosed.

Led · Series A · Feb 2021

AerWave Medical, Inc. is advancing an interventional approach designed to treat severe asthma, chronic obstructive pulmonary disease (COPD), and other advanced lung diseases. The company is targeting significant U.S. addressable markets that include roughly 4 million COPD patients and 2.5 million asthma patients. Management emphasizes that AerWave holds broad intellectual property protection around its technology, which it believes creates defensible competitive advantages. Led by CEO Jeff O’Donnell, the executive team has prior experience in building and exiting medical-device ventures. Proceeds from its recent financing will be directed toward continued development of the AerWave technology and preparation for broader clinical use worldwide. While revenue and user metrics have not been disclosed, the company’s focus remains on product development and clinical validation.